Associated Papers
PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma.
Stewart J et al.
Oncogene, 2025
39939726 (PubMed )
Supplement: 41388_2024_3265_MOESM2_ESM.xlsx › Sheet1
The theory of massively repeated evolution and full identifications of cancer-driving nucleotides (CDNs).
Zhang L et al.
Elife, 2024
39688960 (PubMed )
Supplement: elife-99340-supp1.xlsx › CDN.Missense.gnomad
Novel Variants of PPP2R1A in Catalytic Subunit Binding Domain and Genotype-Phenotype Analysis in Neurodevelopmentally Delayed Patients.
Qian Y et al.
Genes, 2023
Uterine lavage identifies cancer mutations and increased TP53 somatic mutation burden in individuals with ovarian cancer.
Ghezelayagh TS et al.
Cancer Research Communications, 2022
36311816 (PubMed )
Supplement: crc-22-0314-s02.xlsx › Table_S6_List_of_mutations
Whole-exome Sequencing of Nigerian Prostate Tumors from the Prostate Cancer Transatlantic Consortium (CaPTC) Reveals DNA Repair Genes Associated with African Ancestry.
White JA et al.
Cancer Research Communications, 2022
36922933 (PubMed )
Supplement: crc-22-0136-s01.xlsx › ST3_Known_Somatic_Variants
Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.
O'Connor CM et al.
Oncogene, 2020
Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.
Haesen D et al.
Cancer Research, 2016
HEAT repeat 1 motif is required for B56γ-containing protein phosphatase 2A (B56γ-PP2A) holoenzyme assembly and tumor-suppressive function.
Nobumori Y et al.
The Journal of Biological Chemistry, 2012
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
Jones S et al.
Science (new York, N.y.), 2010
Select a paper to view details